NCT07916389
Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (4)
Arms and interventions
* Neoadjuvant Treatment: Participants with ALK fusions will receive neoadjuvant treatment (4 Courses) with alectinib. * Surgery * Adjuvant Therapy: Participants will receive adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).
* Neoadjuvant Treatment: Participants with NTRK 1/2/3 or ROS1 fusions will receive neoadjuvant (4 Courses) treatment with entrectinib. * Surgery * Adjuvant Therapy: Participants will receive adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).
* Neoadjuvant Treatment: Participants no RTK fusion or RTK fusions other than ALK, ROS1 or NTRK1/2/3 (including MET fusion) will receive neoadjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses). * Surgery * Adjuvant Therapy: Participants will receive adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).
Participants who have no measurable residual disease at the time of enrollment. * Adjuvant Therapy: Participants will receive adjuvant chemotherapy with carboplatin, etoposide, and cyclophosphamide (4 courses).
Drugs: Alectinib, Entrectinib, Cyclophosphamide, Etoposide, Carboplatin
Procedures: Surgery
Biologicals: Filgrastim, Pegfilgrastim
Sites
1 site in 1 country
- St. Jude Children's Research HospitalMemphis, Tennessee, United States